Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07161414 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

A Phase 1 study of Advanced Solid Tumors, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
11
Study locations

NCT07161414 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 40 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower). The trial reports 11 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07161414, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standard of care therapy for whom immunooncology (IO) monotherapy would be deemed appropriate by the investigator.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG IV Rilvegostomig
  • DRUG Recombinant Human Hyaluronidase (rHu)
  • DRUG SC Rilvegostomig
  • DRUG SC rilvegostomig + rHu

Study Locations (11)

Other

  • Research Site - Seoul
  • Research Site - Seoul
  • Research Site - Barcelona
  • Research Site - Barcelona
  • Research Site - Madrid
  • Research Site - Madrid
  • Research Site - Newcastle upon Tyne
  • Research Site - Sutton

North Carolina

  • Research Site - Huntersville

Texas

  • Research Site - San Antonio

Virginia

  • Research Site - Fairfax

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-11-25
Est. Completion 2029-07-24
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07161414

The ClinicalTrials.gov registry entry for NCT07161414 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (80% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which IV Rilvegostomig is the first listed.

NCT07161414 reports 11 study locations spanning 4 distinct geographic areas - top geographies include Other, North Carolina, Texas.

Frequently Asked Questions

What is clinical trial NCT07161414 about?

NCT07161414 is a clinical study titled "A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy". The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with standa...

What is the current status of trial NCT07161414?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-11-25. Estimated completion is 2029-07-24.

What conditions does trial NCT07161414 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT07161414?

The interventions under investigation include: IV Rilvegostomig (DRUG), Recombinant Human Hyaluronidase (rHu) (DRUG), SC Rilvegostomig (DRUG), SC rilvegostomig + rHu (DRUG).

Who is sponsoring clinical trial NCT07161414?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07161414 being conducted?

This trial has 11 study locations across North Carolina, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.